Famciclovir 250 mg Tablet

Adult dose

1. Treatment of herpes zoster Adults: Administer famciclovir 250 mg orally 3 times daily for 7 days. It is preferable to start treatment as soon as symptoms appear after infection. 2. Treatment of an initial episode of genital herpes Adults: Administer 250 mg of this medicine orally 3 times daily for 5 days. It is preferable to start treatment as soon as symptoms appear after infection. 3. Treatment of acute recurrent genital herpes Adults: Administer 125 mg of this medicine orally twice daily for 5 days. It is preferable to start treatment during the prodromal period or as soon as symptoms appear after infection. 4. Suppression of recurrent genital herpes Adults: Administer 250 mg of this medicine orally twice daily. Interrupt treatment periodically every 6～12 months to assess whether the natural course of the disease has changed. 5. Patients with renal impairment 1) Treatment of herpes zoster and an initial episode of genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg twice daily Creatinine clearance (mL/min/1.73㎡) 10～29: 250 mg once daily 2) Treatment of acute recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 125 mg twice daily Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg once daily 3) Suppression of recurrent genital herpes: Creatinine clearance (mL/min/1.73㎡) 30～59: 250 mg twice daily Creatinine clearance (mL/min/1.73㎡) 10～29: 125 mg twice daily 4) If only serum creatinine is known, creatinine clearance can be calculated using the following formula. Men: {body weight (kg) × (140-age)}/ {72 × serum creatinine (mg/dL)} Women: 0.85 × the value calculated for men 5) Patients with renal impairment undergoing hemodialysis For patients undergoing hemodialysis, administration every 48 hours is preferable, taking the dialysis interval into consideration. Four hours of hemodialysis reduces the plasma concentration of this medicine by approximately 75%; therefore, administer this medicine immediately after dialysis. The recommended dose is 250mg for patients with herpes zoster and 125mg for patients with genital herpes. 6. Patients with hepatic impairment: No dose adjustment is necessary in patients with chronic compensated liver disease. There is insufficient treatment experience in patients with overt chronic decompensated liver disease; therefore, no clear recommended dose has been established.

This medicine should not be taken by certain patients. Individuals who are allergic to this medicine or its components, or have genetic issues like lactose intolerance, should not take this medication. Patients with kidney function issues should pay special attention when using this medicine. Symptoms such as headache, dizziness, nausea, and vomiting may occur during treatment, and if symptoms are severe, consultation with a healthcare professional is advised. This medication does not completely cure genital herpes, and it is important to avoid sexual contact when symptoms are present during treatment. It is recommended to maintain safe sexual practices. If symptoms such as dizziness, drowsiness, or confusion occur during treatment, it is advised to refrain from driving or operating machinery. In patients with severely compromised liver function, the efficacy of this medication may be diminished, requiring caution. This medication may interact with other drugs, so it is crucial to inform your doctor or pharmacist if you are taking other medications. Dosage adjustments may be necessary, especially when taken with drugs that affect renal excretion. Women who are pregnant or breastfeeding should carefully consider the risks and benefits of using this medication, and the same applies to women who may become pregnant. The safety and effectiveness of this medication have not been established in children under 18 years of age, so it is not recommended for use in this group. For the elderly, dosage adjustments are usually not required; however, in cases of decreased kidney function, dosage adjustments should be made. In case of overdose, it is essential to visit a medical institution immediately for appropriate treatment, and blood dialysis can reduce the concentration of this medication. This medication should be stored in a sealed container to protect it from air and moisture, in a cool, dry place at a temperature below 30 degrees Celsius, and kept out of reach of children; it is also advisable not to transfer it to another container.

• Headache
• nausea
• thrombocytopenia
• leukopenia
• neutropenia
• dizziness
• confusion
• drowsiness
• hallucinations
• palpitations

This medication should be stored in a sealed container to protect it from air and moisture, and kept in a cool, dry place at a temperature below 30 degrees Celsius.

Appearance

White round film-coated tablet

Package unit

21 tablets (7 tablets × 3)/PTP